共 13 条
- [1] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) : 1870 - 1880Bloomgren, GaryRichman, SandraHotermans, ChristopheSubramanyam, MeenaGoelz, SusanNatarajan, AmyLee, SophiaPlavina, TatianaScanlon, James V.Sandrock, AlfredBozic, Carmen
- [2] Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (11) : 1067 - 1074Chen, YipingBord, EvelynTompkins, TroyMiller, JaniceTan, Chen S.Kinkel, R. PhilipStein, Marion C.Viscidi, Raphael P.Ngo, Long H.Koralnik, Igor J.
- [3] A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy[J]. BRAIN, 2004, 127 : 1970 - 1978Du Pasquier, RAKuroda, MJZheng, YJean-Jacques, JLetvin, NLKoralnik, IJ
- [4] A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis[J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (06) : 708 - 719Holmen, CarolinaPiehl, FredrikHillert, JanFogdell-Hahn, AnnaLundkvist, MalinKarlberg, ElinNilsson, PetraDahle, CharlotteFeltelius, NilsSvenningsson, AndersLycke, JanOlsson, Tomas
- [5] Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study[J]. LANCET NEUROLOGY, 2010, 9 (03) : 264 - 272Jilek, SamanthaJaquiery, EmilieHirsch, Hans H.Lysandropoulos, AndreasCanales, MathieuGuignard, LaurenceSchluep, MyriamPantaleo, GiuseppeDu Pasquier, Renaud A.
- [6] Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring[J]. LANCET NEUROLOGY, 2011, 10 (08) : 745 - 758Kappos, LudwigBates, DavidEdan, GillesEraksoy, MefkureGarcia-Merino, AntonioGrigoriadis, NikolaosHartung, Hans-PeterHavrdova, EvaHillert, JanHohlfeld, ReinhardKremenchutzky, MarceloLyon-Caen, OlivierMiller, ArielPozzilli, CarloRavnborg, MadsSaida, TakahikoSindic, ChristianVass, KarlClifford, David B.Hauser, StephenMajor, Eugene O.O'Connor, Paul W.Weiner, Howard L.Clanet, MichelGold, RalfHirsch, Hans H.Radue, Ernst-WilhelmSorensen, Per SoelbergKing, John
- [7] Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy[J]. PLOS PATHOGENS, 2012, 8 (11):Perkins, Molly R.Ryschkewitsch, CarolineLiebner, Julia C.Monaco, Maria Chiara G.Himelfarb, DanielleIreland, SaraRoque, AnnelysEdward, Heather L.Jensen, Peter N.Remington, GinaAbraham, ThomasAbraham, JaspreetGreenberg, BenjaminKaufman, CharlesLaGanke, ChrisMonson, Nancy L.Xu, XiaoningFrohman, ElliotMajor, Eugene O.Douek, Daniel C.
- [8] A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) : 899 - 910Polman, CHO'Connor, PWHavrdova, EHutchinson, MKappos, LMiller, DHPhillips, JTLublin, FDGiovannoni, GWajgt, AToal, MLynn, FPanzara, MASandrock, AW
- [9] Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis[J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (01) : 64 - 71Prosperini, LucaGianni, CostanzaLeonardi, LauraDe Giglio, LauraBorriello, GiovannaGalgani, SimonettaPozzilli, CarloGasperini, Claudio
- [10] Natalizumab plus interferon beta-1a for relapsing multiple sclerosis[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) : 911 - 923Rudick, RAStuart, WHCalabresi, PAConfavreux, CGaletta, SLRadue, EWLublin, FDWeinstock-Guttman, BWynn, DRLynn, FPanzara, MASandrock, AWFazekas, FEnzinger, CSeifert, TStorch, MStrasser-Fuchs, SBerger, TDilitz, EEgg, RDeisenhammer, FDecoo, DLampaert, JBartholome, EBier, JStenager, ERasmussen, MBinzer, MShorsh, KChristensen, MRavnborg, MSorensen, PSBlinkenberg, MPetersen, BHansen, HJBech, EPetersen, TKirkegaard, MEralinna, JRuutiainen, JSoilu-Hänninen, MSäkö, ELaaksonen, MReunanen, MRemes, AKeskinarkaus, IMoreau, TNoblet, MRouaud, OCouvreur, G